Price
CHART BY
Frequently asked questions
What is Bioatla's market capitalization?
The market capitalization of Bioatla is $23.68M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Bioatla?
Bioatla's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.70. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Bioatla's stock?
Currently, 4 analysts cover Bioatla's stock, with a consensus target price of $8.667. Analyst ratings provide insights into the stock's expected performance.
What is Bioatla's revenue over the trailing twelve months?
Over the trailing twelve months, Bioatla reported a revenue of $11.00M.
What is the EBITDA for Bioatla?
Bioatla's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$85.17M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Bioatla?
Bioatla has a free cash flow of -$85.08M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Bioatla have, and what sector and industry does it belong to?
Bioatla employs approximately 65 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Bioatla's shares?
The free float of Bioatla is 49.70M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $23.68M
- EPS (TTM)
- -$1.70
- Free Float
- 49.70M
- Revenue (TTM)
- $11.00M
- EBITDA (TTM)
- -$85.17M
- Free Cashflow (TTM)
- -$85.08M
Pricing
- 52W span
- $0.38$4.02
Analyst Ratings
The price target is $8.667 and the stock is covered by 4 analysts.
Buy
3
Hold
1
Sell
0
Information
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
- Employees
- 65
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US09077B1044
- Primary Ticker
- BCAB
Finance data from FactSet